SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending as reports of Iran's Supreme Leader's confirmed death following US-Israeli strikes, coupled with subsequent Iranian retaliatory attacks and escalating shipping disruptions in the Strait of Hormuz, are driving widespread community speculation about significant oil supply concerns.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Mounting geopolitical tensions in the Middle East, marked by widespread missile strikes and threats to critical shipping lanes like the Strait of Hormuz, are driving a substantial war risk premium into crude oil, prompting the community to heavily discuss and rotate into the energy sector, expecting XLE to see significant upside.

Direxion Shares ETF Trust - Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares (GUSH) is trending as the community speculates on escalating geopolitical tensions in the Middle East, particularly around potential US-Iran conflict and its impact on critical oil supply routes. Investors are actively discussing the "war trade" and positioning for significant upward movement in oil prices and the energy exploration sector.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is highly active as escalating geopolitical tensions, particularly regarding potential conflict in the Middle East, intensify investor focus on defense stocks, with the community actively anticipating substantial gains from increased military spending and significant new U.S. defense budget proposals.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as US and Israeli military operations in Iran reportedly eliminated the Supreme Leader, igniting a polarizing debate between those celebrating a decisive blow against a hostile regime and critics who perceive it as a dangerous escalation and a potential diversion from recent Epstein file revelations, raising concerns over geopolitical stability and market volatility.

United States Commodity Funds LLC - United States Copper Index Fund

CPER is experiencing significant investor attention, driven by widespread community anticipation of a major copper price surge. This bullish sentiment stems from escalating global demand, particularly from AI data centers and electrification initiatives, which are colliding with growing supply deficits and strategic geopolitical efforts to secure critical mineral supplies.

Fan Tokens allow fans across multiple sports verticals to exercise their share of influence within their favourite teams/leagues/clubs. Through Socios.com, fans are empowered to participate in certain club decisions, for example, choosing a goal celebration song in a football stadium, choosing which fighters should go head to head in MMA, and more. Thanks to Fan Tokens, holders receive access to once-in-a-lifetime experiences such as player meet and greets, training day events &amp; much much more.  The growing list of partnerships launching their Fan Tokens on the Socios.com platform includes some of the biggest sporting organizations in the world such as FC Barcelona, Inter Milan, AC Milan, Manchester City, UFC, ROUSH Fenway Racing, Aston Martin, just to name a few.

Italian National Football Team Fan Token

ITA is trending amidst escalating global geopolitical tensions, particularly from conflicts in the Middle East, driving investor discussion around defense stocks. The community is actively debating the sector's resilience and its role as a potential hedge, even as some traders take profits after recent rallies.

ProShares Trust - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is trending due to intensifying geopolitical risks, notably reports of an oil tanker incident and concerns over a potential wider conflict in the Middle East, sparking robust debate among investors about imminent oil supply disruptions versus the persistent global crude oversupply.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending amidst escalating geopolitical tensions, driving community discussion around its pivotal role as a prime defense contractor with a massive order backlog and recent technical breakout, signaling strong bullish sentiment in the sector.

Patterson-UTI Energy, Inc. engages in the provision of drilling and pressure pumping services, directional drilling, rental equipment, and technology. It operates through the following segments: Drilling Services, Completion Services, and Drilling Products. The Drilling Services segment represents contract drilling, directional drilling, oilfield technology, and electrical controls and automation businesses. The Completion Services segment offers hydraulic fracturing, wireline and pumping, completion support, cementing, and pressure pumping business. The Drilling Products segment focuses on manufacturing and distribution of drill bits business. The company was founded by Cloyce A. Talbott and A. Glenn Patterson in 1978 and is headquartered in Houston, TX.

Patterson-UTI Energy Inc

Patterson-UTI Energy is trending after reporting strong Q4 results that beat expectations, driven by robust Completion Services and cost efficiencies. The community is actively discussing the company's solid turnaround and its strengthened position within a consolidating oil and gas sector, eyeing sustained growth as market fundamentals tighten.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>After the adjustment, Intensity Therapeutics stock will begin trading on February 19, retaining the ticker symbol INTS.</li><li>The stock consolidation will reduce the total shares outstanding from approximately 63.3 million to about 2.53 million.</li><li>In January, the company said it raised more than $20 million in 2025, extending its cash runway into the second quarter of 2027.&nbsp;</li></ul>Intensity Therapeutics, Inc. (INTS) on Friday announced a 1-for-25 reverse stock split approved by its board and shareholders, aiming to boost the per-share price of its common stock to meet Nasdaq’s minimum listing requirements.The reverse split, scheduled to take effect at 4:01 p.m. ET on February 18, will consolidate every 25 existing shares into a single new share.<h2 class="st-heading-2">Changes After The Reverse Split</h2>After the adjustment, Intensity Therapeutics stock will begin trading on February 19, under a new CUSIP number 45828J 202 while retaining the ticker symbol INTS.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/INTS">Intensity Therapeutics stock&nbsp;</a>traded 25% lower on Friday morning.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;Intensity is a late-stage biotech company developing its own cancer treatments. It uses a special drug-linking technology to create therapies that aim to destroy tumors and help the immune system better detect cancer.<h2 class="st-heading-2">Impact on Shareholders</h2>The stock consolidation will reduce the total shares outstanding from approximately 63.3 million to about 2.53 million. No fractional shares will be issued; instead, shareholders entitled to a fraction will receive cash payments based on the adjusted closing price on February 18.Alongside the split, the company will make proportional changes to stock options, warrants, convertible securities, and shares issued under its stock incentive programs. The total number of authorized shares will remain unchanged.In January, the company outlined its 2025 achievements and mapped out priorities for 2026 as it advances INT230-6, its lead cancer therapy designed to destroy tumors and stimulate immune response. Intensity raised more than $20 million in 2025, extending its cash runway into the second quarter of 2027.&nbsp;INTS stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-slips-premarket-ev-headwinds-mount-wall-street-sees-upside-physical-ai-future/cZR5NHfR4sm">Tesla Stock Slips Premarket As EV Headwinds Mount — But One Wall Street Firm Sees Over 30% Upside On A ‘Physical AI’ Future</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did INTS Stock Plummet 25% Today? 

Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.

Equity

Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.


Intensity Therapeutics Announces Reverse Stock Split

Intensity Therapeutics Announces Reverse Stock Split Intensity Therapeutics Announces Reverse Stock Split PR Newswire SHELTON, Conn., Feb. 13, 2026 Intensity's common stock is expected to begin...

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities PR Newswire SHELTON...

All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy

Intensity Therapeutics Inc. (INTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium...

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's...

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast...

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR...

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of...

<ul class="summary-bullets"><li>In heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved a disease control rate of 75%.</li><li>In patients with metastatic sarcoma receiving only INT230-6, the median overall survival was 21.3 months, the company noted.</li><li>CEO Lewis H. Bender said that the company has initiated randomized controlled studies, including a late-stage study in sarcoma. &nbsp;</li></ul>Shares of Intensity Therapeutics, Inc. (INTS) jumped 282% on Thursday morning after the company announced the publication of positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers.In heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved a disease control rate of 75% and a median overall survival of 11.9 months in the trial, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.intensitytherapeutics.com/news-events/press-releases/detail/112/intensity-therapeutics-inc-announces-publication-of">said</a>.In patients with metastatic sarcoma receiving only INT230-6, the median overall survival was 21.3 months, the company noted. In a clinical trial, measuring the median overall survival is one way to assess the effectiveness of a new treatment.INT230-6 induced a qualitative decrease in proliferating cancer cells in injected tumors, and pharmacokinetic results showed that greater than 95% of the active cytotoxic agents remained in the injected tumors, Intensity Therapeutics said.Furthermore, 15 of 64 patients in the trial survived for more than 21 months, the company noted.<h2 class="st-heading-2">What Did Company Executives Say?</h2>“Given the drug's mechanism of action and the data reported in this paper from over 20 types of metastatic solid cancers, such as breast, sarcoma, pancreatic, lung, and head and neck, we believe the study results show the potential of INT230-6 to achieve clinical benefit for metastatic patients of multiple cancer types with or without the use of radiation, systemic drugs or immunotherapy.” Lewis H. Bender, CEO, Intensity TherapeuticsThe CEO added that the company has initiated randomized controlled studies, including a late-stage study in sarcoma. This rare cancer originates in the body's connective tissues, such as bone, muscle, fat, and cartilage.INT30-6 consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule. In addition to local disease control and direct tumor killing, it causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INTS">INTS stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.INTS stock is down 42% this year and approximately 67% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sensei-biotherapeutics-halts-lead-drug-development-explores-sale-or-merger-options/cLGFvQbR3xf">Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Retail Going Gaga Over INTS Stocks Today?

The firm announced positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers, with 15 of 64 patients in the trial surviving for more than 21 months.

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Intensity Therapeutics Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

INTS
INTENSITY THERAPEUTICS, INC.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INTS News

INTSINTENSITY THERAPEUTICS, INC.